Local targeting of the CD200-CD200R axis does not promote corneal graft survival

Susan M Nicholls; David A Copland; Andrea Vitova; Lucia Kuffova; John V Forrester; Andrew D Dick

doi:10.1016/j.exer.2014.11.006

Local targeting of the CD200-CD200R axis does not promote corneal graft survival

Susan M Nicholls, David A Copland, Andrea Vitova, Lucia Kuffova, John V Forrester, Andrew D Dick

Applied Medicine

Research output: Contribution to journal › Article › peer-review

3 Citations (Scopus)

Abstract

Corneal graft rejection is primarily a CD4(+) T cell-mediated mechanism in which macrophages may play an important inflammatory role. CD200Fc fusion protein is an artificial agonist of CD200R1, a receptor expressed predominantly on myeloid cells, engagement of which is known to down-regulate macrophage function. We therefore wished to test whether CD200Fc could be used as a therapeutic agent to prolong corneal graft survival. The distribution of CD200R1 and CD200, its natural ligand, was examined by immunohistology in the cornea and conjunctiva of unoperated rats and rats that had received corneal allografts. Mouse CD200Fc was injected subconjunctivally into transplanted rats on six occasions from the day of surgery until day 10 after transplantation. Control groups received injections of mouse IgG or diluent PBS. Allo-transplants were also performed in CD200(-/-) and control mice. The ability of CD200Fc to bind rat macrophages in vitro and to inhibit nitric oxide production was tested. Mean day of rejection in CD200Fc, IgG and PBS-treated rats was 12, 10 and 9 respectively (p=0.24). Mean day of rejection in CD200(-/-) and wild type mice was 17.5 and 16.0 respectively (p=0.07). Mouse CD200Fc bound to rat macrophages in a dose-dependent manner, but was unable to inhibit nitric oxide production. The fact that treatment with CD200Fc did not inhibit graft rejection and the failure of CD200 deficiency to affect graft survival suggests that local targeting of the CD200-CD200R axis to suppress macrophage activation is not a useful therapeutic strategy in corneal graft rejection.

Original language	English
Pages (from-to)	1-8
Number of pages	8
Journal	Experimental Eye Research
Volume	130
Early online date	11 Nov 2014
DOIs	https://doi.org/10.1016/j.exer.2014.11.006
Publication status	Published - Jan 2015

Bibliographical note

Copyright © 2014 Elsevier Ltd. All rights reserved.
Funding was provided by the Royal College of Surgeons (Edinburgh) and the National Eye Research Centre. The work was further supported by the National Institute for Health Research (NIHR) Biomedical Research Centre based at Moorfields Eye Hospital NHS Foundation Trust and UCL Institute of Ophthalmology. Funding sources had no involvement in the conduct of the research or manuscript preparation and submission. The views expressed are those of the authors and not necessarily those of the NHS, the NIHR or the Department of Health. The authors thank Genentech for the gift of mouse CD200Fc fusion protein and Dr Jian Liu for expert technical assistance with confocal microscopy. We also acknowledge the use of the University of Bristol Flow Cytometry Facility and assistance of Dr. Andrew Herman.

Keywords

corneal transplantation
graft rejection
CD200
macrophage
immunotherapy
rat
mouse

Access to Document

10.1016/j.exer.2014.11.006Licence: Unspecified

Cite this

@article{3cc63b1b34bb48f0a4c8ec6a47fe82eb,

title = "Local targeting of the CD200-CD200R axis does not promote corneal graft survival",

abstract = "Corneal graft rejection is primarily a CD4(+) T cell-mediated mechanism in which macrophages may play an important inflammatory role. CD200Fc fusion protein is an artificial agonist of CD200R1, a receptor expressed predominantly on myeloid cells, engagement of which is known to down-regulate macrophage function. We therefore wished to test whether CD200Fc could be used as a therapeutic agent to prolong corneal graft survival. The distribution of CD200R1 and CD200, its natural ligand, was examined by immunohistology in the cornea and conjunctiva of unoperated rats and rats that had received corneal allografts. Mouse CD200Fc was injected subconjunctivally into transplanted rats on six occasions from the day of surgery until day 10 after transplantation. Control groups received injections of mouse IgG or diluent PBS. Allo-transplants were also performed in CD200(-/-) and control mice. The ability of CD200Fc to bind rat macrophages in vitro and to inhibit nitric oxide production was tested. Mean day of rejection in CD200Fc, IgG and PBS-treated rats was 12, 10 and 9 respectively (p=0.24). Mean day of rejection in CD200(-/-) and wild type mice was 17.5 and 16.0 respectively (p=0.07). Mouse CD200Fc bound to rat macrophages in a dose-dependent manner, but was unable to inhibit nitric oxide production. The fact that treatment with CD200Fc did not inhibit graft rejection and the failure of CD200 deficiency to affect graft survival suggests that local targeting of the CD200-CD200R axis to suppress macrophage activation is not a useful therapeutic strategy in corneal graft rejection.",

keywords = "corneal transplantation, graft rejection, CD200, macrophage, immunotherapy, rat , mouse",

author = "Nicholls, {Susan M} and Copland, {David A} and Andrea Vitova and Lucia Kuffova and Forrester, {John V} and Dick, {Andrew D}",

note = "Copyright {\textcopyright} 2014 Elsevier Ltd. All rights reserved. Funding was provided by the Royal College of Surgeons (Edinburgh) and the National Eye Research Centre. The work was further supported by the National Institute for Health Research (NIHR) Biomedical Research Centre based at Moorfields Eye Hospital NHS Foundation Trust and UCL Institute of Ophthalmology. Funding sources had no involvement in the conduct of the research or manuscript preparation and submission. The views expressed are those of the authors and not necessarily those of the NHS, the NIHR or the Department of Health. The authors thank Genentech for the gift of mouse CD200Fc fusion protein and Dr Jian Liu for expert technical assistance with confocal microscopy. We also acknowledge the use of the University of Bristol Flow Cytometry Facility and assistance of Dr. Andrew Herman.",

year = "2015",

month = jan,

doi = "10.1016/j.exer.2014.11.006",

language = "English",

volume = "130",

pages = "1--8",

journal = "Experimental Eye Research",

issn = "0014-4835",

publisher = "Academic Press Inc.",

}

TY - JOUR

T1 - Local targeting of the CD200-CD200R axis does not promote corneal graft survival

AU - Nicholls, Susan M

AU - Copland, David A

AU - Vitova, Andrea

AU - Kuffova, Lucia

AU - Forrester, John V

AU - Dick, Andrew D

N1 - Copyright © 2014 Elsevier Ltd. All rights reserved. Funding was provided by the Royal College of Surgeons (Edinburgh) and the National Eye Research Centre. The work was further supported by the National Institute for Health Research (NIHR) Biomedical Research Centre based at Moorfields Eye Hospital NHS Foundation Trust and UCL Institute of Ophthalmology. Funding sources had no involvement in the conduct of the research or manuscript preparation and submission. The views expressed are those of the authors and not necessarily those of the NHS, the NIHR or the Department of Health. The authors thank Genentech for the gift of mouse CD200Fc fusion protein and Dr Jian Liu for expert technical assistance with confocal microscopy. We also acknowledge the use of the University of Bristol Flow Cytometry Facility and assistance of Dr. Andrew Herman.

PY - 2015/1

Y1 - 2015/1

N2 - Corneal graft rejection is primarily a CD4(+) T cell-mediated mechanism in which macrophages may play an important inflammatory role. CD200Fc fusion protein is an artificial agonist of CD200R1, a receptor expressed predominantly on myeloid cells, engagement of which is known to down-regulate macrophage function. We therefore wished to test whether CD200Fc could be used as a therapeutic agent to prolong corneal graft survival. The distribution of CD200R1 and CD200, its natural ligand, was examined by immunohistology in the cornea and conjunctiva of unoperated rats and rats that had received corneal allografts. Mouse CD200Fc was injected subconjunctivally into transplanted rats on six occasions from the day of surgery until day 10 after transplantation. Control groups received injections of mouse IgG or diluent PBS. Allo-transplants were also performed in CD200(-/-) and control mice. The ability of CD200Fc to bind rat macrophages in vitro and to inhibit nitric oxide production was tested. Mean day of rejection in CD200Fc, IgG and PBS-treated rats was 12, 10 and 9 respectively (p=0.24). Mean day of rejection in CD200(-/-) and wild type mice was 17.5 and 16.0 respectively (p=0.07). Mouse CD200Fc bound to rat macrophages in a dose-dependent manner, but was unable to inhibit nitric oxide production. The fact that treatment with CD200Fc did not inhibit graft rejection and the failure of CD200 deficiency to affect graft survival suggests that local targeting of the CD200-CD200R axis to suppress macrophage activation is not a useful therapeutic strategy in corneal graft rejection.

AB - Corneal graft rejection is primarily a CD4(+) T cell-mediated mechanism in which macrophages may play an important inflammatory role. CD200Fc fusion protein is an artificial agonist of CD200R1, a receptor expressed predominantly on myeloid cells, engagement of which is known to down-regulate macrophage function. We therefore wished to test whether CD200Fc could be used as a therapeutic agent to prolong corneal graft survival. The distribution of CD200R1 and CD200, its natural ligand, was examined by immunohistology in the cornea and conjunctiva of unoperated rats and rats that had received corneal allografts. Mouse CD200Fc was injected subconjunctivally into transplanted rats on six occasions from the day of surgery until day 10 after transplantation. Control groups received injections of mouse IgG or diluent PBS. Allo-transplants were also performed in CD200(-/-) and control mice. The ability of CD200Fc to bind rat macrophages in vitro and to inhibit nitric oxide production was tested. Mean day of rejection in CD200Fc, IgG and PBS-treated rats was 12, 10 and 9 respectively (p=0.24). Mean day of rejection in CD200(-/-) and wild type mice was 17.5 and 16.0 respectively (p=0.07). Mouse CD200Fc bound to rat macrophages in a dose-dependent manner, but was unable to inhibit nitric oxide production. The fact that treatment with CD200Fc did not inhibit graft rejection and the failure of CD200 deficiency to affect graft survival suggests that local targeting of the CD200-CD200R axis to suppress macrophage activation is not a useful therapeutic strategy in corneal graft rejection.

KW - corneal transplantation

KW - graft rejection

KW - CD200

KW - macrophage

KW - immunotherapy

KW - rat

KW - mouse

U2 - 10.1016/j.exer.2014.11.006

DO - 10.1016/j.exer.2014.11.006

M3 - Article

C2 - 25450061

SN - 0014-4835

VL - 130

SP - 1

EP - 8

JO - Experimental Eye Research

JF - Experimental Eye Research

ER -

Local targeting of the CD200-CD200R axis does not promote corneal graft survival

Abstract

Bibliographical note

Keywords

Access to Document

Fingerprint

Cite this